Importantly, we found that inhibition of PPM1D, or stimulation of p53 by inhibition of MDM2, suppresses the survival of Ppm1dT/+ HSPCs and thus could be potentially utilized for preventing the development of therapy-induced myeloid neoplasms in patients carrying PPM1D truncating mutations. Here, PPM1D is linked to myeloid neoplasm.